Collectively, these results indicate the absence of a broad therapeutic effect of elevated muscle PGC-1α on dysferlinopathy and in some cases, even an acceleration of disease progression. Here, PPARGC1A is linked to neuromuscular disease caused by qualitative or quantitative defects of dysferlin.